- Conditions
- Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Interventions
- BTP-114
- Drug
- Lead sponsor
- Placon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 3,361
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vorinostat, paclitaxel, carboplatin, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Solid Tumors
- Interventions
- INCB186748, Cetuximab, GEMNabP, mFOLFIRINOX
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more
- Conditions
- Tumors
- Interventions
- Bavituximab
- Drug
- Lead sponsor
- Peregrine Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Santa Monica, California • Memphis, Tennessee + 3 more
- Conditions
- Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
- Interventions
- KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors, Pancreatic Cancer
- Interventions
- ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Sarasota, Florida + 2 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pelitinib, temsirolimus
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Advanced Magnetic Resonance Imaging, Conventional Magnetic Resonance Imaging, Gadolinium-Chelate, Iopamidol
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pegylated liposomal doxorubicin hydrochloride, picoplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- TY-2136b
- Drug
- Lead sponsor
- TYK Medicines, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island • Houston, Texas
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
- Interventions
- XB010, Pembrolizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Malignant Solid Tumor, Solid Tumor, Metastatic Tumor
- Interventions
- LY2334737
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Cancers
- Interventions
- MEGF0444A, bevacizumab, paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 2 more
- Conditions
- Advanced Solid Tumor
- Interventions
- PTX-35
- Drug
- Lead sponsor
- Pelican Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Portland, Oregon • Austin, Texas • San Antonio, Texas
- Conditions
- Solid Tumor
- Interventions
- Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Solid Tumor, Adult
- Interventions
- BGB-24714, Paclitaxel, Carboplatin, Docetaxel
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Sarasota, Florida • St. Petersburg, Florida + 12 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • St Louis, Missouri
- Conditions
- Advanced Solid Tumors, Cancer, Advanced Solid Malignancies
- Interventions
- AZD7762, Irinotecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee
- Conditions
- Malignant Solid Tumour
- Interventions
- INNO-206
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Neoplasms by Site
- Interventions
- Relatlimab, Nivolumab, BMS-986213
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 17
- States / cities
- La Jolla, California • Aurora, Colorado • Tampa, Florida + 14 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
- Interventions
- PF-08052666
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more
- Conditions
- Neoplasm Metastasis, Non-Small Cell Lung Cancer
- Interventions
- zongertinib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more
- Conditions
- Advanced EGFR Positive Solid Tumor
- Interventions
- ZZ06
- Biological
- Lead sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Fairway, Kansas • The Bronx, New York
- Conditions
- Unspecified Adult Solid Tumor
- Interventions
- sorafenib tosylate, pemetrexed disodium, laboratory biomarker analysis, biopsy
- Drug · Other · Procedure
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia